- Home
- DSP vs AQST Comparison
DSP vs AQST Comparison
Compare DSP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- AQST
- Stock Information
- Founded
- DSP 1999
- AQST 2004
- Country
- DSP United States
- AQST United States
- Employees
- DSP N/A
- AQST N/A
- Industry
- DSP EDP Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- AQST Health Care
- Exchange
- DSP Nasdaq
- AQST Nasdaq
- Market Cap
- DSP 291.3M
- AQST 274.4M
- IPO Year
- DSP 2021
- AQST 2018
- Fundamental
- Price
- DSP $12.24
- AQST $2.84
- Analyst Decision
- DSP Strong Buy
- AQST Strong Buy
- Analyst Count
- DSP 7
- AQST 7
- Target Price
- DSP $23.29
- AQST $10.57
- AVG Volume (30 Days)
- DSP 658.1K
- AQST 1.5M
- Earning Date
- DSP 03-03-2025
- AQST 03-05-2025
- Dividend Yield
- DSP N/A
- AQST N/A
- EPS Growth
- DSP N/A
- AQST N/A
- EPS
- DSP 0.14
- AQST N/A
- Revenue
- DSP $289,235,000.00
- AQST $57,561,000.00
- Revenue This Year
- DSP $13.31
- AQST N/A
- Revenue Next Year
- DSP $16.25
- AQST $35.72
- P/E Ratio
- DSP $86.47
- AQST N/A
- Revenue Growth
- DSP 29.74
- AQST 13.80
- 52 Week Low
- DSP $7.77
- AQST $2.24
- 52 Week High
- DSP $26.33
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- DSP 24.79
- AQST 48.60
- Support Level
- DSP $12.76
- AQST $2.45
- Resistance Level
- DSP $13.77
- AQST $3.06
- Average True Range (ATR)
- DSP 1.28
- AQST 0.22
- MACD
- DSP -0.71
- AQST 0.02
- Stochastic Oscillator
- DSP 4.39
- AQST 63.93
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.